Last reviewed · How we verify

NCT05127746

Phase 1 Clinical Trial of DA-5207 in Healthy Adults

Completed Phase 1 Last updated 14 April 2023
What this trial tests

Phase 1 trial testing Aricept 5mg Tablet in Healthy in 51 participants. Completed in 13 December 2022.

Timeline
25 November 2021
Primary endpoint
13 December 2022
13 December 2022

Quick facts

Lead sponsorDong-A ST Co., Ltd.
PhasePhase 1
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designcrossover
Maskingnone
Primary purposetreatment
Enrollment51
Start date25 November 2021
Primary completion13 December 2022
Estimated completion13 December 2022
Sites1 location across South Korea

Drugs / interventions tested

Conditions studied

Sponsor

Dong-A ST Co., Ltd. — full company profile →

Who can join

Adults 19 to 55, any sex, with Healthy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to evaluate the safety, pharmacokinetics and pharmacodynamics of DA-5207 transdermal delivery system in healthy adults

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Aricept 5mg Tablet

Trials testing the same drug.

Other recruiting trials for Healthy

Currently open trials in the same condition.

Other Dong-A ST Co., Ltd. trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05127746.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing